{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:47:15Z","timestamp":1792025235625,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) carries a poor prognosis, and older patients and those with impaired performance status are often underrepresented in randomized trials. This study evaluated real-world treatment patterns, survival outcomes, and factors associated with outcome in older patients with GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 63 patients aged\u2009\u2265\u200965 years with a diagnosis of GBM managed at a single-center radiation oncology department between 2014 and 2023. Overall survival (OS) and progression-free survival (PFS) were calculated from diagnosis. Multivariable Cox models included age, sex, Karnofsky Performance Status (KPS), radiologically confirmed gross total resection (GTR), and temozolomide (TMZ) administration as clinically prespecified covariates. Complete-case analyses were performed. Proportional hazards assumptions were assessed using Schoenfeld residuals, with additional time-varying and exploratory sensitivity analyses addressing diagnostic classification, treatment selection, concomitant TMZ exposure, and treatment timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median OS was 7.0 months (95% CI 5.3\u201314.4) and median PFS was 5.3 months (95% CI 3.9\u20137.8). In the multivariable OS model (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200956; 50 deaths), increasing age was associated with higher mortality (HR 1.09, 95% CI 1.02\u20131.17;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), whereas female sex was associated with a lower hazard of death (HR 0.45, 95% CI 0.23\u20130.91;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025). Omission of TMZ was associated with higher mortality (HR 2.26, 95% CI 1.16\u20134.41;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), while GTR showed a directionally favorable association that did not reach conventional statistical significance (HR 0.52, 95% CI 0.27\u20131.01;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.054). In the PFS model (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200956; 53 events), increasing age (HR 1.07, 95% CI 1.01\u20131.14;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027) and omission of TMZ (HR 2.34, 95% CI 1.20\u20134.55;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013) were associated with higher hazards, whereas female sex (HR 0.45, 95% CI 0.23\u20130.89;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022) and higher KPS (HR 0.98, 95% CI 0.96\u20131.00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039) were associated with lower hazards. Resection status violated the proportional hazards assumption for PFS; time-varying analysis indicated an early favorable association of GTR that attenuated over time. Sensitivity analyses based on concomitant TMZ exposure and survival measured from radiotherapy initiation yielded similar associations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Survival remained limited in this real-world cohort of older patients with GBM. Age, sex, performance status, resection status, and TMZ administration showed varying associations with outcome, with TMZ showing the most consistent association across analyses. Given the small retrospective cohort and substantial treatment selection, these findings should be considered hypothesis-generating rather than causal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-026-08457-9","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:21Z","timestamp":1791920241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence on the management and outcomes of glioblastoma in elderly patients: a monocentric retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0843-7373","authenticated-orcid":false,"given":"J\u00f6rg Andreas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Schirrwagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Pitzschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Medenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"8457_CR1","doi-asserted-by":"publisher","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329:574\u2013587. https:\/\/doi.org\/10.1001\/jama.2023.0023. PMID: 36809318.","DOI":"10.1001\/jama.2023.0023."},{"key":"8457_CR2","doi-asserted-by":"publisher","unstructured":"Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764\u2013772. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3002. PMID: 23209033.","DOI":"10.1158\/1078-0432.CCR-12-3002."},{"key":"8457_CR3","doi-asserted-by":"publisher","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106. PMID: 34185076.","DOI":"10.1093\/neuonc\/noab106"},{"key":"8457_CR4","doi-asserted-by":"publisher","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765\u2013773. https:\/\/doi.org\/10.1056\/NEJMoa0808710. PMID: 19228619.","DOI":"10.1056\/NEJMoa0808710"},{"key":"8457_CR5","doi-asserted-by":"publisher","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al. Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015;372:2499\u20132508. https:\/\/doi.org\/10.1056\/NEJMoa1407279. PMID: 26061753.","DOI":"10.1056\/NEJMoa1407279"},{"key":"8457_CR6","doi-asserted-by":"publisher","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331. PMID: 15758010.","DOI":"10.1056\/NEJMoa043331"},{"key":"8457_CR7","doi-asserted-by":"publisher","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330. PMID: 15758009.","DOI":"10.1056\/NEJMoa043330"},{"key":"8457_CR8","doi-asserted-by":"publisher","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318:2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718. PMID: 29260225.","DOI":"10.1001\/jama.2017.18718"},{"key":"8457_CR9","doi-asserted-by":"publisher","unstructured":"Gramatzki D, Roth P, Rushing EJ, Weller J, Andratschke N, Hofer S, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018;29:1431\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdy106","DOI":"10.1093\/annonc\/mdy106"},{"key":"8457_CR10","doi-asserted-by":"publisher","unstructured":"Nava F, Tramacere I, Fittipaldo A, Bruzzone MG, Dimeco F, Fariselli L et al. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997\u20132010. Neuro Oncol. 2014;16:719\u2013727. https:\/\/doi.org\/10.1093\/neuonc\/not316. PMID: 24463354.","DOI":"10.1093\/neuonc\/not316"},{"key":"8457_CR11","doi-asserted-by":"publisher","unstructured":"Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527\u201335. https:\/\/doi.org\/10.1056\/NEJMoa065901.","DOI":"10.1056\/NEJMoa065901"},{"key":"8457_CR12","doi-asserted-by":"publisher","unstructured":"Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583\u20131588. https:\/\/doi.org\/10.1200\/JCO.2004.06.082. PMID: 15051755.","DOI":"10.1200\/JCO.2004.06.082"},{"key":"8457_CR13","doi-asserted-by":"publisher","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017;376:1027\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa1611977. PMID: 28296618.","DOI":"10.1056\/NEJMoa1611977"},{"key":"8457_CR14","doi-asserted-by":"publisher","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916\u2013926. doi:10.1016\/S1470-2045(12)70265-6. PMID: 22877848. https:\/\/doi.org\/10.1016\/S1470-2045(12)70265-6","DOI":"10.1016\/S1470-2045(12)70265-6"},{"key":"8457_CR15","doi-asserted-by":"publisher","unstructured":"Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118:786\u2013798. https:\/\/doi.org\/10.3171\/2012.10.JNS112268. PMID: 23176331.","DOI":"10.3171\/2012.10.JNS112268"},{"key":"8457_CR16","doi-asserted-by":"crossref","unstructured":"Tsang DS, Khan L, Perry JR, Soliman H, Sahgal A, Keith JL et al. Survival outcomes in elderly patients with glioblastoma. Clin Oncol (R Coll Radiol). 2015;27:176\u2013183. doi:10.1016\/j.clon.2014.11.026. PMID: 25549930.","DOI":"10.1016\/j.clon.2014.11.026"},{"key":"8457_CR17","doi-asserted-by":"publisher","unstructured":"Nunna RS, Khalid SI, Patel S, Sethi A, Behbahani M, Mehta AI et al. Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. World Neurosurg. 2021;149:e1026\u2013e1037. https:\/\/doi.org\/10.1016\/j.wneu.2021.01.028. PMID: 33482415.","DOI":"10.1016\/j.wneu.2021.01.028"},{"key":"8457_CR18","doi-asserted-by":"publisher","unstructured":"Moraes FY, Lo A, Morgan ER, Millar B-A, Shultz DB, Maurice C et al. Management and Outcomes in the Oldest-Old Population with Glioblastoma. Can J Neurol Sci. 2018;45:199\u2013205. https:\/\/doi.org\/10.1017\/cjn.2017.278. PMID: 29249210.","DOI":"10.1017\/cjn.2017.278"},{"key":"8457_CR19","doi-asserted-by":"publisher","unstructured":"Stadler C, Gramatzki D, Le Rhun E, Hottinger AF, Hundsberger T, Roelcke U et al. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. Neurooncol Pract. 2024;11:132\u2013141. https:\/\/doi.org\/10.1093\/nop\/npad070. PMID: 38496908.","DOI":"10.1093\/nop\/npad070"},{"key":"8457_CR20","doi-asserted-by":"publisher","unstructured":"Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D et al. International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and\/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015;33:4145\u20134150. 10.1200\/JCO.2015.62.6606 https:\/\/doi.org\/10.1200\/JCO.2015.62.6606. PMID: 26392096.","DOI":"10.1200\/JCO.2015.62.6606"},{"key":"8457_CR21","doi-asserted-by":"publisher","unstructured":"Reihanian Z, Abbaspour E, Zaresharifi N, Karimzadhagh S, Mahmoudalinejad M, Sourati A et al. Impact of Age and Gender on Survival of Glioblastoma Multiforme Patients: A Multicenter Retrospective Study. Cancer Rep (Hoboken). 2024;7:e70050. https:\/\/doi.org\/10.1002\/cnr2.70050. PMID: 39506810.","DOI":"10.1002\/cnr2.70050"},{"key":"8457_CR22","doi-asserted-by":"crossref","unstructured":"Hallaert G, Pinson H, van den Broecke C, van Roost D, Kalala JP, Boterberg T. Sex-based survival differences in IDH-wildtype glioblastoma: Results from a retrospective cohort study. J Clin Neurosci. 2021;91:209\u2013213. doi:10.1016\/j.jocn.2021.07.008. PMID: 34373029.","DOI":"10.1016\/j.jocn.2021.07.008"},{"key":"8457_CR23","doi-asserted-by":"publisher","unstructured":"Murakami R, Hirai T, Nakamura H, Furusawa M, Nakaguchi Y, Uetani H et al. Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval. Jpn J Radiol. 2012;30:193\u2013197. https:\/\/doi.org\/10.1007\/s11604-011-0031-x. PMID: 22183828.","DOI":"10.1007\/s11604-011-0031-x"},{"key":"8457_CR24","doi-asserted-by":"publisher","unstructured":"Tu Z, Xiong H, Qiu Y, Li G, Wang L, Peng S. Limited recurrence distance of glioblastoma under modern radiotherapy era. BMC Cancer. 2021;21:720. https:\/\/doi.org\/10.1186\/s12885-021-08467-3. PMID: 34154559.","DOI":"10.1186\/s12885-021-08467-3"},{"key":"8457_CR25","doi-asserted-by":"publisher","unstructured":"Zheng L, Zhou Z-R, Yu Q, Shi M, Yang Y, Zhou X et al. The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy. Front Oncol. 2020;10:615368. https:\/\/doi.org\/10.3389\/fonc.2020.615368. PMID: 33692942.","DOI":"10.3389\/fonc.2020.615368"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-026-08457-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-08457-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-08457-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:09:58Z","timestamp":1792022998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-026-08457-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8457"],"URL":"https:\/\/doi.org\/10.1186\/s12877-026-08457-9","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. The study was approved by the Ethics Committee of the Medical Faculty of Martin Luther University Halle-Wittenberg (approval number: 2024-002). Owing to the retrospective nature of the study, the requirement for informed consent was waived by the Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1296"}}